AVIR Aviragen Therapeutics, Inc.

0.60
+0  (1%)
Previous Close 0.60
Open 0.60
Price To book 0.83
Market Cap 23.31M
Shares 38,649,000
Volume 23,843
Short Ratio 0.92
Av. Daily Volume 184,344

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data released February 1, 2017 - primary endpoint not met.
BTA585
Respiratory syncytial virus (RSV)
Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
BTA074 5% topical gel
Condyloma
Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
Vapendavir - SPIRITUS trial
Human rhinovirus (HRV)
Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Laninamivir Octanoate - IGLOO
Adults with symptomatic influenza A or B infection

Latest News

  1. ETFs with exposure to Aviragen Therapeutics, Inc. : April 5, 2017
  2. Blog Coverage Aviragen to Explore Strategic Alternatives; Cuts Headcount by 25%
  3. Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update
  4. Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q2, 2017 By the Numbers : March 21, 2017
  5. Aviragen Tanks on Second Antiviral Drug Failure
  6. Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
  7. Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results
  8. Aviragen Hits 52-Week Low After Drug Fails Trial
  9. Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585
  10. Aviragen Therapeutics to Host Conference Call to Report Second Quarter Fiscal Year 2017 Financial Results on February 2, 2017
  11. Aviragen Therapeutics Inc (AVIR) Could Start To Move Near Term
  12. Edited Transcript of AVIR earnings conference call or presentation 3-Nov-16 8:30pm GMT
  13. Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: Q1, 2017 By the Numbers : November 7, 2016
  14. ETF’s with exposure to Aviragen Therapeutics, Inc. : October 31, 2016
  15. Aviragen Therapeutics, Inc. :AVIR-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016

SEC Filings

  1. 8-K - Current report 17739465
  2. 8-K - Current report 17734604
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 17607694
  4. 8-K - Current report 17600675
  5. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17600466
  6. SC 13G/A (Amend) - Statement of acquisition of beneficial ownership by individuals 17599846
  7. 10-Q - Quarterly report (Sections 13 or 15(d)) 17575365
  8. 8-K - Current report 17571344
  9. 8-K - Current report 17567299
  10. 8-K - Current report 17516262